Compass Pathways Gains 1.2% as Six-Month Phase 3 Data Confirms Drug Durability
CMPS•Compass Pathways’ stock ticked up 1.2% after analysts praised durability of its COMP360 psilocybin therapy based on six-month data from a second Phase 3 depression trial. The trial showed sustained symptom reduction through six months without additional dosing, bolstering its planned FDA filing timetable.
1. Six-Month Phase 3 Data Validates Durability
The second Phase 3 trial of COMP360 in treatment-resistant depression delivered sustained symptom reduction through six months following a single dosing session. Patients maintained response levels without additional retreatment, indicating a durable therapeutic profile that addresses relapse concerns in current depression therapies.
2. Analyst Endorsement Drives Share Rise
Following publication of the six-month results, multiple analysts reiterated buy ratings and highlighted the long-term efficacy of COMP360. That positive sentiment lifted Compass Pathways shares by approximately 1.2% in early trading, reflecting renewed confidence in the therapy’s commercial prospects.
3. Upcoming FDA Submission and Outlook
Compass Pathways is preparing an NDA submission for COMP360 with the FDA by year-end, aiming for a potential U.S. approval in 2027. The company is also evaluating regulatory pathways in Europe and exploring partnerships to support global launch and reimbursement discussions.
